// App-Quantinova.ai

P738 : Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remitters

Researchers

Presenter

  • R Hardi

Principal Investigators

  • B Bokemeyer

  • W Sandborn

  • W Reinisch

  • I Shafran

  • A Stallmach

  • R Ehehalt

  • P Geransar

  • J M Khalid

  • D Tudor

  • S Schreiber

Medical Centers

  • Capital Digestive Care, Chevy Chase Clinical Research, Chevy Chase, USA

  • Gastroenterology Practice, Minden, Germany

  • University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA

  • Medical University, Department of Internal Medicine III, Vienna, Austria

  • Shafran Gastroenterology Research Center, Winter Park, USA

  • Jena University Hospital, Internal Medicine I, Jena, Germany,

  • Praxis für Gastroenterologie, Heidelberg, Germany

  • Takeda Pharmaceuticals International AG, GI Rare Medical Affairs, Zurich, Switzerland

  • Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Christian Albrechts University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany

Locations

  • United States

  • Germany

  • Austria

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00783692

  • NCT00790933

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved